Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 24, 2020

Lundbeck gets FDA nod for migraine prevention drug Vyepti

Lundbeck, a Danish pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for its Vyepti as a preventive treatment for migraine in adult patients.

Lundbeck headquarters in Valby, Denmark. Photo: courtesy of H. Lundbeck A/S.